Who Me?
Well-Known Member
Brincidofovir fails Phase III CMV trial
Brincidofovir fails Phase III CMV trial. Did physicians mistake diarrhea for GVHD?
Chimerix announced that the Phase III trial of brincidofovir has failed to meet its primary endpoint of suppressing CMV infection through week 24 after hematopoietic cell transplant (HCT) patients. Although the drug showed impressive suppression of CMV infections during the 14 week trial, infections soared during the 10-week observation period that followed. One theory presented by the company’s CEO is that physicians may have mistaken drug related diarrhea for GHVD and administered unnecessary steroids.
VIEW POST
http://hhv6foundation.wpengine.com
Brincidofovir fails Phase III CMV trial. Did physicians mistake diarrhea for GVHD?
Chimerix announced that the Phase III trial of brincidofovir has failed to meet its primary endpoint of suppressing CMV infection through week 24 after hematopoietic cell transplant (HCT) patients. Although the drug showed impressive suppression of CMV infections during the 14 week trial, infections soared during the 10-week observation period that followed. One theory presented by the company’s CEO is that physicians may have mistaken drug related diarrhea for GHVD and administered unnecessary steroids.
VIEW POST
http://hhv6foundation.wpengine.com